Algin Or Derivative Patents (Class 536/3)
  • Patent number: 10190237
    Abstract: A method for preparing a salt-resistant and detergent-resistant alginate fiber by contacting and infiltrating a finished alginate fiber with a borate-containing adjuvant solution and using selected proper raw materials in selected proportions and reaction conditions. The preparation method solves the problem that the alginate fiber and a fabric made therefrom are neither salt-resistant nor detergent-resistant. The borate-modified alginate fiber and a fabric made therefrom have excellent salt resistances, and can be washed with an alkaline detergent. The swelling degree of the alginate fiber modified by the adjuvant solution can be reduced to 39.8% after the fiber is immersed in a normal saline at 30° C. for 72 h and can be reduced to 55.3% after the fiber is immersed in a standard detergent for 24 h, while the fiber maintains its original morphology without any obvious dissolution phenomenon, and the self flame-resisting performance of the alginate fiber is also maintained.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 29, 2019
    Assignee: QINGDAO UNIVERSITY
    Inventors: Yanzhi Xia, Xing Tian, Fangfang Cheng, Bingbing Wang, Fengyu Quan, Quan Ji
  • Patent number: 9561252
    Abstract: A Product is described and which contains at least one type of ligand bound to a separation material and which allows selective binding or cleavage of a biomolecule for example in human blood.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: February 7, 2017
    Assignee: GLYCOREX TRANSPLANTATION AB
    Inventor: Kurt G. I. Nilsson
  • Patent number: 9283543
    Abstract: Modified diamond particles for use in chromatography with a desired functional group at the diamond surface, formed from reaction of hydroxyl groups at diamond surfaces with a reactive molecule.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: March 15, 2016
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Matthew R. Linford, David Scott Jensen, Landon Andrew Wiest
  • Patent number: 9095509
    Abstract: A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation is also disclosed.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: August 4, 2015
    Assignee: Genzyme Corporation
    Inventors: Hitesh R. Bhagat, Jeffrey M. Goldberg
  • Publication number: 20150105344
    Abstract: The invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of ?-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedure that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2˜6 and the temperature of 100˜120° C., and adjusted pH to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 16, 2015
    Inventors: Meiyu Geng, Huashi Guan, Xianliang Xin, Zhao Yang, Guangqiang Sun
  • Patent number: 8986667
    Abstract: The present invention relates to a mixture, having a skin-tightening effect, which is made up of: 10 to 80% by weight of a polysaccharide, preferably of an alginate, having a molecular weight of less than 600,000 Daltons, preferably less than 400,000 Daltons and more preferably less than 200,000 Daltons, 15 to 75% by weight of a polyhydroxylated agent selected from sugars and their derivatives, particularly sugar esters and sugar, ethers, preferably sorbitol, 3 to 15% by weight of poly(vinyl alcohol) or polyvinylpyrrolidone, and 0 to 25% by weight of cellulose or of a derivative of cellulose, such as carboxymethylcellulose or hydroxymethylcellulose. The present invention also relates to cosmetic compositions which contain this mixture. These cosmetic compositions enable a mechanical smoothing of the surface of the skin to be obtained progressively with great comfort of use and enables a good fixing of make-up products.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: March 24, 2015
    Assignee: LVMH Recherche
    Inventors: Hervé Delage-Grouiller, Brigitte Noe, Christian Mahe
  • Patent number: 8980238
    Abstract: Because of the formation of disulfide bridges with mucus glycoproteins, the mucoadhesive properties of polymeric compounds can be significantly improved by the covalent attachment of thiol substructures to them. By the transformation of free thiol groups on such polymers in disulfides with mercaptonicotinamides or mercaptopyridoxins these thiol groups become comparatively more reactive resulting in significantly improved mucoadhesive properties. Furthermore, polymers exhibiting disulfide partial structures with mercaptonicotinamides or mercaptopyridoxins do not need to be protected against oxidation. In addition, they show comparatively higher permeation enhancing properties.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: March 17, 2015
    Assignees: Thiomatrix Forschungs—Und Beratungs GmbH, Croma Pharma GmbH
    Inventor: Johannes Leierer
  • Publication number: 20150064143
    Abstract: The present invention provides an ionically cross-linkable alginate-grafted hyaluronate compound containing alginate and hyaluronate, the alginate and the hyaluronate forming a covalent linkage. The use of the compound can easily provide a cross-linked hyaluronate by adding a divalent cation without using a chemical cross-linking agent. The present invention also provides a method for cell transplantation that includes preparing a composition comprising the compound of claim 1 and cells for transplantation, and administering to a subject in need thereof the composition.
    Type: Application
    Filed: September 3, 2014
    Publication date: March 5, 2015
    Inventors: Kuen Yong LEE, Hong Hyun PARK
  • Publication number: 20150050499
    Abstract: Disclosed herein is a fibrosis-causing agent in a particulate form which effectively reduces the lung capacity in a noninvasive manner.
    Type: Application
    Filed: August 19, 2014
    Publication date: February 19, 2015
    Inventors: SUGURU HATA, YUICHI TADA, AYAKA AKUTAGAWA
  • Patent number: 8946194
    Abstract: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: February 3, 2015
    Assignee: Board of Regents, University of Texas System
    Inventors: Sarah Mayes, Christine E. Schmidt
  • Publication number: 20140348815
    Abstract: Microencapsulation of bioactive and chemical cargo in a stable, cross-linked polymer matrix is presented that results in small particle sizes and is easily scaled-up for industrial applications. A formulation of a salt of an acid soluble multivalent ion, an acid neutralized with a volatile base and one or more monomers that cross-link in the presence of multivalent ions is atomized into droplets. Cross-linking is achieved upon atomization where the volatile base is vaporized resulting in a reduction of the pH of the formulation and the temporal release of multivalent ions from the salt that cross-link the monomers forming a capsule. The incorporation of additional polymers or hydrophobic compounds in the formulation allows control of hydration properties of the particles to control the release of the encapsulated compounds. The operational parameters can also be controlled to affect capsule properties such as particle-size and particle-size distribution.
    Type: Application
    Filed: May 27, 2014
    Publication date: November 27, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Tina Jeoh-Zicari, Herbert B. Scher, Monica C. Santa-Maria, Scott Strobel
  • Publication number: 20140338564
    Abstract: An alginate monomer structure with metal crystallite embedded includes a first alginate monomer and at least a first metal crystallite. The first alginate monomer is composed of a first uronate molecule and a second uronate molecule, which are linked linearly to each other. A first carbonyl group is formed on a second carbon atom (C2) of the main ring in the first uronate molecule, a carboxyl group is presented on a sixth carbon atom (C6) of the main ring in the second uronate molecule, and a first intramonomer glycosidic linkage is presented between a first carbon atom (C1) of the main ring in the first uronate molecule and a fourth carbon atom (C4) of the main ring in the second uronate molecule. The first metal crystallite is associated between the first uronate molecule and the second uronate molecule.
    Type: Application
    Filed: May 14, 2014
    Publication date: November 20, 2014
    Applicant: HOPEWANG ENT CO., LTD
    Inventor: YUNG-PIN LI
  • Publication number: 20140296496
    Abstract: This invention relates to an extraction process of brown algae polysaccharides in a field of pharmaceutical chemistry. This invention particularly discloses a process of extracting brown algae polysaccharides based on a microwave chemistry method and brown algae polysaccharides obtained by said process. The process of the invention comprises: 1) putting pulverized brown algae powder into a microwave reaction chamber, adding acid solution to conduct reaction; optionally concentrating the mixer, and then washing with organic solvent to remove excess acid; conducting grading alcohol precipitation after water extract to obtain mannuronic acid rich fragment (M rich) algin, fucoidan and/or laminaran respectively; and adding an alkali solution to the brown algae residue to conduct alkaline digestion, filtering the residue off, adjusting pH of the filtrate to neutral, conducting alcohol precipitation to obtain guluronic acid rich fragment (G rich) algin precipitates.
    Type: Application
    Filed: November 1, 2012
    Publication date: October 2, 2014
    Inventors: Jinsong Zhang, Mingtian Li, Zhiyu Liu, Lei Xu
  • Publication number: 20140260468
    Abstract: A biodegradable iron-crosslinked alginate is useful as a remediation agent for environmental contaminants such as phosphate. When charged with phosphate, or other nutrients, the iron-functionalized alginate can be used as an agricultural fertilizer.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: NDSU RESEARCH FOUNDATION
    Inventors: ACHINTYA BEZBARUAH, TALAL BAKHEET ALMEELBI, MICHAEL QUAMME
  • Patent number: 8835403
    Abstract: The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of ?-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120° C., and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: September 16, 2014
    Inventors: Meiyu Geng, Huashi Guan, Xianliang Xin, Zhao Yang, Guangqiang Sun
  • Publication number: 20140227370
    Abstract: A polysaccharide fibre useful in biomedical applications such as wound management is made as a bicomponent fibre with alginate and psyllium polymers. An antimicrobial silver salt may be incorporated. The fibre may be made by extruding an aqueous mixture of alkaline-solubilised psyllium and sodium alginate into a calcium chloride bath.
    Type: Application
    Filed: December 5, 2012
    Publication date: August 14, 2014
    Applicant: University of Bolton
    Inventors: Mohsen Miraftab, Rashid Masood
  • Publication number: 20140219941
    Abstract: The present disclosure relates generally to cosmetic powders having improved dispersibility, feel, and stability in which the powders are surface modified with at least one alginic acid, or salt form thereof. The powders may be used in cosmetic compositions such as a powder foundation skin toner, skin lotion, or body wash.
    Type: Application
    Filed: February 6, 2013
    Publication date: August 7, 2014
    Applicant: U.S. Cosmetic Corporation
    Inventors: Shoji TAKEKAWA, Katsumi SHIMIZU
  • Patent number: 8765937
    Abstract: A process for the ultrapurification of alginates is provided. In particular, the process may be used for microencapsulation in human cell transplants.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: July 1, 2014
    Assignee: GH Care, Inc.
    Inventors: Giuseppe Pietro Pio Basta, Riccardo Calafiore
  • Patent number: 8759282
    Abstract: A film comprising as a film-forming agent an alginate salt of monovalent cation or a mixture of alginate salts containing at least one alginate salt of monovalent cation, the film-forming agent being such that a 10% aqueous solution thereof at a temperature of 20° C. has a viscosity of 100-1000 mPas, as measured at a shear rate of 20 rpm by use of a Brookfield viscometer with a spindle No. 2. A method of preparing the film. The film is useful for delivery of active ingredients to a mammal.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: June 24, 2014
    Assignee: Uppsalagruppen Medical AB
    Inventors: Kjell G Stenberg, Fredrik Hubinette
  • Patent number: 8742013
    Abstract: The present disclosure provides polymer compounds binding with lipoamide produced by the reaction of the primary amine group of lipoamide with the carboxy group of polysaccharide compounds such as chondroitin sulfates, carboxymethyl celluloses, or hyaluronic acids; functional compounds such as peptides, proteins, growth factors; or drugs; or biocompatible polymers such as poly(ethylene oxide), poly(vinyl alcohol), or poly(vinyl pyrrolidone). The present disclosure also provides their synthesis methods, products of hydrogels and films using the same as and methods for manufacturing the products.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: June 3, 2014
    Assignee: Seoul National University of Technology Center for Industrial Collaboration
    Inventors: Insup Noh, Seongyeun Jo, Doyeon Kim, Junghoon Woo
  • Patent number: 8741872
    Abstract: Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: June 3, 2014
    Assignee: FMC Biopolymer AS
    Inventors: Jan Egil Melvik, Michael Dornish, Edvar Onsoyen, Astrid B. Berge, Terje Svendsen
  • Publication number: 20140147452
    Abstract: The present invention provides novel mucoadhesive compounds useful in the prevention of diseases and disorders of or which are associated with the mucosal membrane.
    Type: Application
    Filed: February 3, 2014
    Publication date: May 29, 2014
    Applicant: POLYRIZON LTD.
    Inventors: Tomer IZRAELI, Smadar COHEN, Robert S. MARKS
  • Patent number: 8691791
    Abstract: There is provided a new use of microspheres comprising a water-insoluble, water-swellable polymer which is anionically charged at pH7, and electrostatically associated with the polymer, in releasable form, a cationically charged chemotherapeutic agent, in the manufacture of a composition for use in the treatment of a brain tumor, wherein in the treatment the composition is introduced into the brain and the chemotherapeutic agent is released from the microspheres, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water. Compositions comprising the microspheres and methods for the treatment of brain tumors are also provided.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: April 8, 2014
    Assignee: Biocompatibles UK Limited
    Inventors: Andrew Lennard Lewis, Yiqing Tang, Peter William Stratford
  • Patent number: 8686053
    Abstract: The present invention discloses an alginic acid and/or its salts with low molecular weight, wherein the weight average molecular weight of the alginic acid is from about 700 to about 4500 Daltons, and the molar ratio of guluronic acid to mannuronic acid in the alginic acid is from about 0.6 to about 19. The present invention also discloses the preparative method of making the alginic acid and/or its salts thereof, and the use of them for treating hypertension, chronic renal failure and postprandial hyperglycemia induced by glycosidase. The present invention further discloses pharmaceutical compositions and foods containing the alginic acid with low molecular weight and/or salts thereof as active component.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: April 1, 2014
    Inventors: Chuanxing Yu, Deshan Li
  • Patent number: 8680072
    Abstract: The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g., for disinfection and cleaning purposes.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: March 25, 2014
    Assignee: Algipharma AS
    Inventors: Edvar Onsøyen, Rolf Myrvold
  • Publication number: 20140073599
    Abstract: Plant treatment compositions comprising metal alginate salts as compositions useful in the treatment of plants, particularly food crops. The metal alginate salts are found to be effective in the absence of herbicides, fungicides and pesticides.
    Type: Application
    Filed: March 9, 2009
    Publication date: March 13, 2014
    Inventors: Tak Wai Cheung, Kenneth Roger Muzyk, John Edward Frieden, Jaheo Cha, Olaf Moberg, Susan Oeltjen, Christopher Rueb, Willie Hendrickson
  • Publication number: 20140045218
    Abstract: A surfactant produced by reacting naturally occurring polysaccharides that are not water soluble with a hydrophilic substituent on a carboxylic portion of the polysaccharide. In a second reaction, the surfactant is further substituted on a hydroxylic portion with a hydrophobic or lipophilic substituent, so as to make the reaction product both water soluble and capable of attracting oily material that is hydrophobic to be removed from a substrate by cleaning in water. Methods of making the surfactant and the follow-on reaction product are described.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 13, 2014
    Applicant: University of Massachusetts
    Inventors: Zarif Farhana Mohd Aris, Ryan M. Bouldin, Ramaswamy Nagarajan, Bridgette Budhlall, Vishal Bavishi
  • Publication number: 20130253074
    Abstract: Disclosed herein is a hyaluronic acid epoxide derivative film comprises a polymer containing a hydroxyl (—OH) terminal group. The film is prepared by allowing an epoxy crosslinker to react with a mixture of hyaluronic acid and a polymer containing a hydroxyl (—OH) terminal group and has improved physical strength, in vivo stability, flexibility, adhesiveness to biological tissue, and biocompatibility.
    Type: Application
    Filed: March 22, 2013
    Publication date: September 26, 2013
    Applicant: GENEWEL CO., LTD
    Inventors: Young Woo Lee, Wan Jin Cho, Ji Yeon Jang
  • Patent number: 8507461
    Abstract: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes, Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: August 13, 2013
    Inventor: Abdalla Rifai
  • Publication number: 20130178426
    Abstract: The invention has as its object the provision of a medicine capable of reducing a volume of emphysema-suffering pulmonary alveoli or alveolar sacs by means of a respiratory region volume inhibitor containing a coating film formation as a main component and capable of forming a coating film in a respiratory region, characterized by being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g/application, preferably 0.07 to 20 g/application and more preferably 0.5 to 5 g/application on each occasion.
    Type: Application
    Filed: August 10, 2011
    Publication date: July 11, 2013
    Applicant: Terumo Kabushiki Kaisha
    Inventors: Takao Anzai, Atsuhiko Nogawa, Yuichi Tada
  • Patent number: 8481695
    Abstract: Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: July 9, 2013
    Assignee: FMC Biopolymer AS
    Inventors: Jan Egil Melvik, Michael Dornish, Edvar Onsoyen, Astrid B. Berge, Terje Svendsen
  • Publication number: 20130149242
    Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.
    Type: Application
    Filed: December 7, 2012
    Publication date: June 13, 2013
    Applicant: Ikaria Development Subsidiary One LLC
    Inventor: Ikaria Development Subsidiary One LLC
  • Patent number: 8445461
    Abstract: The present invention provides pharmaceutical composition for treating Meniere's disease, comprising saccharides or sugar alcohols as an active ingredient and polysaccharides, wherein the ratio by weight of the saccharides or sugar alcohols to the polysaccharides is about 100:2 to 100:50. The pharmaceutical composition of the present invention may eliminate the cathartic effect caused by saccharides or sugar alcohols to ensure the endolymphatic hydrops decompression effect. Therefore the effect of the therapeutic composition of the present invention is improved. The pharmaceutical composition may provide in gel, powder, granule form or the like.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: May 21, 2013
    Assignee: Setsuko Takeda
    Inventor: Setsuko Takeda
  • Patent number: 8426567
    Abstract: Low molecular weight modified pectin, particularly modified citrus pectin (MCP), and/or low molecular weight modified alginate is useful in a composition for stimulating the immune response of a mammal, particularly a human. Modified pectin and/or modified alginate is administered in a composition in an amount sufficient to modulate, support, enhance or extend an immune response, particularly to an individual having an inadequate or reduced immune function. Stimulation of an immune response is evidenced by stimulation of cell-mediated immune function, humoral immune function, phagocytic function of mononuclear macrophages, and NK cell activity. The composition also may comprise well known pharmacologically acceptable agents, such as sulfured amino acids, cilantro, garlic, minerals, and herbs.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: April 23, 2013
    Assignee: Econugenics, Inc.
    Inventor: Isaac Eliaz
  • Patent number: 8389713
    Abstract: A photocrosslinked polysaccharide pseudo-sponge exhibiting a low swelling property and a high degradation ability in vivo while retaining a suitable strength. The polysaccharide pseudo-sponge is produced by a crosslinking reaction of a photoreactive polysaccharide obtained by introducing a photoreactive group into a polysaccharide, and exhibits a low swelling property and a blue dextran-low dyeaffinity.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: March 5, 2013
    Assignee: Seikagaku Corporation
    Inventor: Tomoya Sato
  • Patent number: 8367637
    Abstract: The present invention provides compositions and methods for treating a joint disease containing as an active ingredient thereof a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for treating a joint disease which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing cartilage injuries, suppressing inflammation and pain of joint tissue, inhibiting degeneration of synovial tissue, and inhibiting osteochondral destruction.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: February 5, 2013
    Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa Iwasaki, Akio Minami, Yasuhiko Kasahara, Tatsuya Igarashi, Daisuke Kawamura, Nobuo Ohzawa, Mariko Imai
  • Publication number: 20130029012
    Abstract: Described herein is an edible coating for food products in which the coatings comprises a polysaccharide cross-linked with a cross-linking agent solution. Also described herein are methods for coating food products and forming clusters of food products. The use of the edible coating for extending the shelf-life of food products is also described.
    Type: Application
    Filed: April 8, 2011
    Publication date: January 31, 2013
    Applicant: FRUIT-SYMBIOSE INC.
    Inventor: Genevieve Girard
  • Publication number: 20120308650
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
    Type: Application
    Filed: June 4, 2012
    Publication date: December 6, 2012
    Inventors: Arturo J. Vegas, Minglin Ma, Kaitlin M. Bratlie, Daniel G. Anderson, Robert S. Langer
  • Publication number: 20120276163
    Abstract: The present invention relates to a biologically acceptable composition for the prophylaxis and/or treatment of colorectal cancer comprising an iron chelator, wherein the composition is adapted for the selective targeting of the iron chelator to the colon.
    Type: Application
    Filed: October 26, 2010
    Publication date: November 1, 2012
    Inventors: Chris Tselepis, Tariq Iqbal, Owen James Sansom
  • Publication number: 20120251468
    Abstract: The present invention relates to oral care compositions comprising certain alginates for the treatment of dentine hypersensitivity and to their use.
    Type: Application
    Filed: December 15, 2010
    Publication date: October 4, 2012
    Applicant: Glaxo Group Limited
    Inventor: Charles Richard Parkinson
  • Publication number: 20120251482
    Abstract: The synthesized piperazium salt of KMUPs disclosed in the present invention is characterized by presented pharmaceutics having functions to improve 5-HT function and eNOS expression of KMUPS in lung diseases, such as proliferation, obliteration, pulmonary artery hypertension. The pharmaceutical composition for inhibiting monocrotaline (MCT)-induced proliferation of pulmonary artery includes an effective amount of a complex salt of formula (I): wherein R2 and R4 are each selected independently from the group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group, and a halogen atom; RX contains a carboxylic group donated from one selected from a group consisting of a Statin, a Co-polymer, a poly-?-polyglutamic acid (?-PGA) derivative and sodium CMC; and ?RX substituent is an anion of the carboxylic group carrying a negative charge; and a pharmaceutically accepted carrier.
    Type: Application
    Filed: September 19, 2011
    Publication date: October 4, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventor: Ing-Jun Chen
  • Publication number: 20120225101
    Abstract: Biomaterials that support cell attachment and growth are provided. In one aspect, biomaterials are provided comprising a first polymer matrix comprising reactive amino moieties and a second polymer matrix that interpenetrates with the first polymer matrix, where the second polymer matrix comprises a poly(alkylene oxide) comprising two or more alkylene oxide oligomers joined by gamma-thioether carbonyl linkages. In another aspect, biomaterials are provided comprising at least one biopolymer comprising amino groups, thiol groups, and bifunctional modifiers connecting at least some of the amino groups to at least some of the thiol groups; and at least one poly(alkylene oxide) cross-linked to at least two thiol groups of the biopolymer. The biomaterials may further comprise a pharmacologically active agent or cells. Methods of administering such biomaterials to a patient in need thereof are also provided.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 6, 2012
    Inventors: Weiyuan J. KAO, Yao Fu
  • Patent number: 8221783
    Abstract: Described herein are implantable medical devices comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue. The triggerable bioadhesive property of the polymer can be triggered or activated by exposure to a stimulus. Also, the present invention pertains to methods of making an implantable medical device comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: July 17, 2012
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Michael N. Helmus, Yixin Xu, Barron W. Tenney, Paul L. Valint, Shrirang V. Ranade
  • Publication number: 20120115823
    Abstract: Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.
    Type: Application
    Filed: November 8, 2010
    Publication date: May 10, 2012
    Inventors: John D. Price, Thomas Piccariello, Robert A. Oberlender, Michaela E. Mulhare, Scott B. Palmer
  • Publication number: 20120108676
    Abstract: Disclosed are aerosol-mediated methods for synthesizing particles for biomedical and drug delivery applications. The method is based on the production of particles from sprayed polymeric micro or nano-droplets obtained by, for example, an air-jet nebulization process that is followed by gelation and/or hardening in a crosslinking fluid, non-solvent, precipitating solvent, or supercritical fluid.
    Type: Application
    Filed: November 1, 2011
    Publication date: May 3, 2012
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hugh D.C. Smyth, Ibrahim M. El-Sherbiny
  • Publication number: 20120089084
    Abstract: A plasma coating device for treating a wound comprises a plasma chamber having: one or more electrodes, a gas supply inlet, a plasma outlet exposed to ambient pressure, and an ignition system operatively connected to the electrodes for providing a non-thermal equilibrium plasma within the plasma chamber. An aerosol delivery system is operable to introduce a bioresorbable material as an aerosol into the plasma, to produce a coating on the wound surface.
    Type: Application
    Filed: June 15, 2010
    Publication date: April 12, 2012
    Inventors: Joe O'Keeffe, Peter Dobbyn, John O'Donoghus, Liam O'Neil
  • Publication number: 20120035321
    Abstract: The present disclosure relates to compounds and medical devices activated with a solvophobic material functionalized with a first reactive member and methods of making such compounds and devices.
    Type: Application
    Filed: February 22, 2010
    Publication date: February 9, 2012
    Inventors: Sébastien Ladet, Philippe Gravagna
  • Publication number: 20110280914
    Abstract: Described herein are composites useful in tissue and organ engineering. In one aspect, the composite comprises the reaction product between a macromolecule comprising at least one thiol group and a gold nanoparticle. The thiolated macro-molecule crosslinks with the gold nanoparticle to produce a composite that is useful in anchoring cells. The composites can be used to form multi-layer 3-D structures, where the cells in each layer can aggregate and fuse with one another to form tissues and organs.
    Type: Application
    Filed: December 17, 2009
    Publication date: November 17, 2011
    Applicant: University of Utah Research Foundation
    Inventors: Glenn D. Prestwich, Aleksander Skardel, Jianxing Zhang
  • Publication number: 20110274793
    Abstract: There is provided a purified alginic acid or a salt thereof having a low degree of coloration and a process for producing the same. A depolymerized alginic acid or a salt thereof having a weight-average molecular weight of 300,000 or lower, wherein a degree of coloration, which is defined as the difference in absorbance between 420 nm and 720 nm when a 5% by weight aqueous solution of the alginic acid or a salt thereof is subjected to absorption spectrophotometry using a 1-cm cell, is 0.040 or lower.
    Type: Application
    Filed: January 19, 2010
    Publication date: November 10, 2011
    Applicant: Kao Corporation
    Inventor: Tomohisa Ichiba
  • Patent number: 8053216
    Abstract: A new method to produce formulations of bacterial cellulose that exhibit improved viscosity-modifying properties particularly with low energy applied to effectuate viscosity changes therewith is provided. Such a method includes the novel co-precipitation with a water soluble co-agent that permits precipitation in the presence of excess alcohol to form an insoluble fiber that can than be utilized as a thickener or suspension aid without the need to introduce high energy mixing. Such bacterial cellulose properties have been available in the past but only through highly labor and energy intensive processes. Such an inventive method as now proposed thus provides a bacterial cellulose-containing formulation that exhibits not only properties that are as effective as those for previous bacterial celluloses, but, in some ways, improvements to such previous types. Certain end-use compositions and applications including these novel bacterial cellulose-containing formulations are also encompassed within this invention.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: November 8, 2011
    Assignee: CP Kelco U.S., Inc.
    Inventors: Zhi-Fa Yang, Neil A. Morrison, Todd A. Talashek, David F. Brinkmann, Don DiMasi, You Lung Chen